Notes:

• 2024 External Quality Assurance (EQA) Program for G6PD Quantitative Test in Philippines [EQA Survey Schedule for 2024]
• Annual Summary of External Quality Assurance Survey for G6PD Blood Quantitative Test in Philippines ( 2022 )
• Application Form for Changing Data in G6PD EQA MIS System

---

G6PD EQA MIS System:

 

FAQ :
Website security certificate problem

(EQA) for G6PD Quantitative Test in Taiwan:
Click here to read

|||||||||||||||

---

Introduction:

Glucose-6-phosphate dehydrogenase (G6PD; EC1.1.1.49; MIM305900) deficiency is the most common enzymopathic in humans. A relatively high incidence (>2%) of this enzymopathy, which may cause of neonatal jaundice and acute hemolytic anemia, was found in Southeast Asia. If it is not prevented or treated properly, neonatal jaundice may lead to kernicterus and cause death or permanent neurological damage. The life-threatening hemolytic crises that occur later may cause permanent kidney damage and can be induced by certain drugs or by eating fava beans. In order to reduce these complications, neonatal screening for G6PD deficiency has been carried out in many countries in this region.

In order to assure the reliability and consistence of the G6PD neonatal screening and confirmatory tests among different laboratories, an external quality assurance (EQA) program for screening G6PD activity in neonatal dried blood spots and determination of G6PD activity in hemolysate has been carried out in Taiwan since 1988 and adopted by the Philippines neonatal screening program (Screening test since 1999). 

For the EQA survey on the confirmatory quantitative test (determination of G6PD activity in hemolysate), periodically, three lyophilized QC materials were sent to each participating laboratory on dry ice by speed post delivery. The results of G6PD activity analysis were requested to be returned by facsimile and submitted by internet within 8 days. The external QA results were evaluated and compared to the median of all reports received and the reference value determined by the reference laboratory. The summary report for each survey was published on website within two weeks after the survey started. 

Participating Laboratories

[Angeles University Foundation Medical Center]	[Baguio General Hospital And Medical Center]	[Bataan General Hospital]
[Batangas Regional Hospital]	[Bicol Regional Training and Teaching Hospital, Laboratory Department]	[Brent Hospital & Colleges Incorporated]
[Cagayan Valley Medical Center]	[Cebu Doctors’ University Hospital]	[Davao Medical School Foundation, Inc.]
[Dr. Pablo O. Torre Memorial Hospital]	[Eastern Visayas Regional Medical Center]	[General Santos Doctors’ Hospital]
[Gov. Celestino Gallares Memorial Hospital]	[Ilocos Training and Regional Medical Center, Department of Laboratories]	[Kidapawan Doctors Hospital, Inc.]
[La Vina General Hospital Inc]	[Lipa Medix Medical Center]	[Mariano Marcos Memorial Hospital And Medical Center]
[Mayor Hilarion A Ramiro Sr. Training and Teaching Hospital]	[MCU-FDTMF Hospital]	[Medical Mission Group Hospital and Health Services Cooperative – Puerto Princesa City]
[Our Lady of Lourdes Hospital]	[Polymedic Medical Plaza]	[Region 1 Medical Center]
[Tagum Doctors Hospital]	[The Medical City]	[University of Perpetaul Help Dalta Medical Center]
[UPH-Dr. Jose G.Tamayo Medical Center]	[West Visayas State University Medical Center, Department of Pathology & Clinical Laboratory]

Results :

January 2023~

1. Survey No : RH2023-01 ( Repeatability ) ( PDF )

2. Survey No.: RH2023-02 ( IMP ) ( PDF )

*IMP : Intermediate Measurement Precision ( a.k.a within-laboratory precision ) ( JCGM 200 : 2012, VIM 3rd ed. ； ISO 3534-2:2006 )